Compare Stocks: RNTX, ZSQR, BCYC, and TKNO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.86	$4.19	$3.80 ▼ $9.16	$269.47M	1.55	346,640 shs	330,331 shs
RNTX Rein Therapeutics	$0.74	$0.94	$0.73 ▼ $2.18	$63.08M	1.35	399,467 shs	387,663 shs
TKNO Alpha Teknova	$5.00	$5.08	$1.91 ▼ $6.68	$268.05M	0.64	125,593 shs	46,976 shs
ZSQR Coeptis Therapeutics	$4.81	$9.48	$4.32 ▼ $21.41	$247.38M	-0.19	565,636 shs	299,458 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-0.26%	-11.26%	-19.58%	-51.69%
RNTX Rein Therapeutics	0.00%	-6.81%	-25.63%	-28.41%	-33.57%
TKNO Alpha Teknova	0.00%	+0.60%	-13.64%	+47.06%	+17.92%
ZSQR Coeptis Therapeutics	0.00%	-8.56%	-56.23%	-66.71%	-55.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$3.86	$4.19	$3.80 ▼ $9.16	$269.47M	1.55	346,640 shs	330,331 shs
RNTX Rein Therapeutics	$0.74	$0.94	$0.73 ▼ $2.18	$63.08M	1.35	399,467 shs	387,663 shs
TKNO Alpha Teknova	$5.00	$5.08	$1.91 ▼ $6.68	$268.05M	0.64	125,593 shs	46,976 shs
ZSQR Coeptis Therapeutics	$4.81	$9.48	$4.32 ▼ $21.41	$247.38M	-0.19	565,636 shs	299,458 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	0.00%	-0.26%	-11.26%	-19.58%	-51.69%
RNTX Rein Therapeutics	0.00%	-6.81%	-25.63%	-28.41%	-33.57%
TKNO Alpha Teknova	0.00%	+0.60%	-13.64%	+47.06%	+17.92%
ZSQR Coeptis Therapeutics	0.00%	-8.56%	-56.23%	-66.71%	-55.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.44	Hold	$13.86	258.99% Upside
RNTX Rein Therapeutics	2.25	Hold	$6.00	713.67% Upside
TKNO Alpha Teknova	1.50	Reduce	N/A	N/A
ZSQR Coeptis Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNTX, ZSQR, BCYC, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00
7/20/2026	RNTX Rein Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/17/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	TKNO Alpha Teknova	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/26/2026	RNTX Rein Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/3/2026	BCYC Bicycle Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
6/1/2026	RNTX Rein Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00 ➝ $8.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$61.21M	4.40	N/A	N/A	$8.79 per share	0.44
RNTX Rein Therapeutics	N/A	N/A	$0.06 per share	12.90	($1.07) per share	N/A
TKNO Alpha Teknova	$40.52M	6.62	N/A	N/A	$1.28 per share	3.91
ZSQR Coeptis Therapeutics	$1.36M	181.90	N/A	N/A	$2.63 per share	1.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	8/7/2026 (Estimated)
RNTX Rein Therapeutics	-$49.87M	-$1.90	N/A	N/A	N/A	N/A	N/A	-68.14%	N/A
TKNO Alpha Teknova	-$17.26M	-$0.32	N/A	N/A	N/A	-41.07%	-24.32%	-16.34%	8/5/2026 (Estimated)
ZSQR Coeptis Therapeutics	-$11.92M	-$2.52	N/A	N/A	N/A	-810.04%	-92.29%	-73.52%	N/A

Latest RNTX, ZSQR, BCYC, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	N/A	N/A	N/A	$4.22 million	N/A
8/5/2026	Q2 2026	TKNO Alpha Teknova	-$0.0833	N/A	N/A	N/A	$10.96 million	N/A
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million
5/15/2026	Q1 2026	RNTX Rein Therapeutics	-$0.49	-$0.19	+$0.30	-$0.19	N/A	N/A
5/14/2026	Q1 2026	ZSQR Coeptis Therapeutics	N/A	-$0.65	N/A	-$0.65	N/A	$0.11 million
5/6/2026	Q1 2026	TKNO Alpha Teknova	-$0.0926	-$0.08	+$0.0126	-$0.08	$10.23 million	$11.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A
ZSQR Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	12.08	12.08
RNTX Rein Therapeutics	N/A	0.40	0.40
TKNO Alpha Teknova	0.20	4.59	3.60
ZSQR Coeptis Therapeutics	0.01	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
RNTX Rein Therapeutics	90.89%
TKNO Alpha Teknova	13.81%
ZSQR Coeptis Therapeutics	13.88%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.00%
RNTX Rein Therapeutics	1.50%
TKNO Alpha Teknova	13.20%
ZSQR Coeptis Therapeutics	24.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.81 million	54.45 million	Optionable
RNTX Rein Therapeutics	9	85.54 million	84.26 million	N/A
TKNO Alpha Teknova	240	53.61 million	46.54 million	Not Optionable
ZSQR Coeptis Therapeutics	2	51.43 million	38.96 million	Not Optionable

RNTX, ZSQR, BCYC, and TKNO Headlines

Recent News About These Companies

Z Squared Inc. Signs Definitive Agreement to Acquire 100% of Paradox Data and Its Union County Campus

1 hour ago | prnewswire.com

Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Expands By 120.7%

July 28, 2026 | marketbeat.com

Reviewing Windtree Therapeutics (NASDAQ:WINT) & Coeptis Therapeutics (NASDAQ:ZSQR)

July 24, 2026 | americanbankingnews.com

Z Squared Inc. Terminates At-The-Market Sales Agreement and Committed Equity Forward Purchase Agreement

July 17, 2026 | prnewswire.com

Z Squared Inc. Provides Capital Structure Update

July 15, 2026 | prnewswire.com

Z Squared Inc. Appoints Jeffrey Harris as Chief Technology Officer

June 30, 2026 | prnewswire.com

Z Squared Raises Approximately $15.3 Million in Non-Debt Capital to Advance AI Infrastructure Strategy

June 29, 2026 | prnewswire.com

Russell Indexes Add Z Squared Inc. to Russell 2000® and Russell 3000®

June 29, 2026 | prnewswire.com

Z Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting Up to 150 MW of Firm Power

June 25, 2026 | prnewswire.com

Z Squared to Participate in Maxim Group's AI Data Center Summit

June 9, 2026 | prnewswire.com

Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure Buildout

June 4, 2026 | prnewswire.com

Z Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes

May 27, 2026 | prnewswire.com

Vanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready Power

May 26, 2026 | globenewswire.com

Z Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference Workloads

May 19, 2026 | prnewswire.com

Z Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory Board

May 4, 2026 | prnewswire.com

Z Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MW

April 29, 2026 | prnewswire.com

Z Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global Market

April 28, 2026 | prnewswire.com

Coeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

April 27, 2026 | finanznachrichten.de

Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution

April 27, 2026 | tmcnet.com

Coeptis Therapeutics Receives Shareholder Approval Towards Z Squared Merger

April 27, 2026 | finanznachrichten.de

Z Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market

April 25, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ZSQR, BCYC, and TKNO Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$3.86 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.97 +0.11 (+2.93%)

As of 07/31/2026 07:59 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Rein Therapeutics NASDAQ:RNTX

$0.74 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.75 +0.02 (+2.25%)

As of 07/31/2026 07:56 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Alpha Teknova NASDAQ:TKNO

$5.00 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.97 -0.03 (-0.50%)

As of 07/31/2026 07:34 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Coeptis Therapeutics NASDAQ:ZSQR

$4.81 0.00 (0.00%)

As of 07/31/2026 04:00 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ZSQR, BCYC, and TKNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ZSQR, BCYC, and TKNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ZSQR, BCYC, and TKNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ZSQR, BCYC, and TKNO Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Rein Therapeutics NASDAQ:RNTX

Alpha Teknova NASDAQ:TKNO

Coeptis Therapeutics NASDAQ:ZSQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNTX, ZSQR, BCYC, and TKNO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNTX, ZSQR, BCYC, and TKNO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNTX, ZSQR, BCYC, and TKNO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, ZSQR, BCYC, and TKNO Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

Rein Therapeutics NASDAQ:RNTX

Alpha Teknova NASDAQ:TKNO

Coeptis Therapeutics NASDAQ:ZSQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools